MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 Thumbnail Image Read more about MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022 Thumbnail Image Read more about Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 at the 2022 ASH Annual Meeting Thumbnail Image Read more about Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 at the 2022 ASH Annual Meeting
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at ASH Annual Meeting Thumbnail Image Read more about Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at ASH Annual Meeting
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress Thumbnail Image Read more about Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
Affimed Provides Updated Clinical Data from Phase 1/2 Study from AFM13 Precomplexed Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting Thumbnail Image Read more about Affimed Provides Updated Clinical Data from Phase 1/2 Study from AFM13 Precomplexed Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
Deepening Response of Bexmarilimab in Combination with SoC in Hematological Malignancies: BEXMAB Study Update Thumbnail Image Read more about Deepening Response of Bexmarilimab in Combination with SoC in Hematological Malignancies: BEXMAB Study Update
Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting Thumbnail Image Read more about Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting
Immunitas Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Cancer Immunotherapy IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting Thumbnail Image Read more about Immunitas Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Cancer Immunotherapy IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting Thumbnail Image Read more about ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
